Updated Abbott vs. Dexcom CGM Tale-of-the-tape Analysis
The CGM market continues to be dynamic, most recently with Abbott’s Libre 3 receiving FDA approval (previous FENIX insight) and Dexcom’s G7 approval right around the corner. Both companies represented well at ATTD and ADA, and momentum should continue into EASD (Sept 19-23). With Dexcom’s G7 US approval anticipated soon, FENIX updated its tale-of-the-tape comparative analysis between Abbott’s Libre 2 and 3 vs. Dexcom’s G6 and G7 CGM systems.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.